Halozyme Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 17 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 78.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Halozyme Therapeutics Inc is 8.62, ranking 52 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 354.26M, representing a year-over-year increase of 22.12%, while its net profit experienced a year-over-year increase of 27.89%.
Key Metrics
The current valuation score of Halozyme Therapeutics Inc is 7.16, ranking 94 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 16.63, which is 126.80% below the recent high of 37.71 and 30.15% above the recent low of 11.61.
The current earnings forecast score of Halozyme Therapeutics Inc is 7.11, ranking 117 out of 159 in the Pharmaceuticals industry. The average price target is 77.00, with a high of 92.00 and a low of 56.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Halozyme Therapeutics Inc is 9.71, ranking 7 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 85.44 and the support level at 72.94, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Halozyme Therapeutics Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 104.71%, representing a quarter-over-quarter increase of 2.11%. The largest institutional shareholder is The Vanguard, holding a total of 11.54M shares, representing 9.81% of shares outstanding, with 5.57% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Halozyme Therapeutics Inc is 8.04, ranking 30 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
